Armata Pharmaceuticals, Inc. (ARMP)
| Market Cap | 136.46M +25.1% |
| Revenue (ttm) | 5.54M -19.3% |
| Net Income | -192.18M |
| EPS | -5.27 |
| Shares Out | 37.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,036 |
| Open | 3.730 |
| Previous Close | 3.590 |
| Day's Range | 3.660 - 3.730 |
| 52-Week Range | 2.940 - 16.340 |
| Beta | 1.35 |
| Analysts | Strong Buy |
| Price Target | 17.50 (+376.84%) |
| Est. Earnings | Nov 11, 2026 |
About ARMP
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Financial Performance
In 2025, Armata Pharmaceuticals's revenue was $4.90 million, a decrease of -5.22% compared to the previous year's $5.17 million. Losses were -$173.80 million, 818.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ARMP stock is "Strong Buy." The 12-month stock price target is $17.5, which is an increase of 376.84% from the latest price.
News
Armata Pharmaceuticals receives $3.7M in additional funding from DoW
Armata Pharmaceuticals (ARMP) announced that it has received an additional $3.7M in non-dilutive funds from the U.S. Department of War to support activities associated with the Phase 3 development pro...
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia New commitment is incremental to previously announced DoW funding and expands total no...
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical drug product lots Oral presentation scheduled for today Monday, Sept. 21, 2026 at the 20 th Internatio...
Armata Pharmaceuticals receives FDA Breakthrough Therapy Designation for AP-SA02
Armata Pharmaceuticals (ARMP) announced that the U.S. FDA has granted Breakthrough Therapy designation to AP-SA02, the company’s intravenously administered Staphylococcus aureus multi-phage product ca...
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies Poten...
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi...
Armata Pharmaceuticals announces new published paper on Ar-KM
Armata Pharmaceuticals (ARMP) announced a paper in the Journal of Molecular Biology, a peer-reviewed journal. The publication, titled “Insights into Genome Ejection by a Therapeutic phiKMV-like Bacter...
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hig...
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hig...
Armata Pharmaceuticals Earnings release: Q2 2026
Armata Pharmaceuticals released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Armata Pharmaceuticals Quarterly report: Q2 2026
Armata Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 12, 2026.
Armata Pharmaceuticals Slides: Corporate presentation
Armata Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Armata provides update on AP-SA02 studies
Armata Pharmaceuticals (ARMP) announced significant clinical, regulatory, manufacturing and operational progress supporting advancement of AP-SA02, the Company’s intravenously administered Staphylococ...
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting Four AP-SA02 engineering runs completed; clinical trial material production is the next pla...
Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02
Armata Pharmaceuticals (ARMP) announced that it has received agreement from the U.S. FDA on an Agreed Initial Pediatric Study Plan, which establishes the agreed regulatory framework for the future eva...
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, In...
Armata Pharmaceuticals granted $2.5M additional non-dilutive award funding
Armata Pharmaceuticals (ARMP) has received an additional $2.5M of non-dilutive funding pursuant to a previously announced Department of Defense award, received through the Medical Technology Enterpris...
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Com...
Armata Pharmaceuticals Slides: Corporate presentation
Armata Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year
Reports Q1 revenue $0.8M vs. $0.5M last year. “Our top priority in 2026 is advancing Armata’s lead Staphylococcus aureus therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in…
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Comp...
Armata Pharmaceuticals Quarterly report: Q1 2026
Armata Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 13, 2026.
Armata Pharmaceuticals Earnings release: Q1 2026
Armata Pharmaceuticals released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals (ARMP) announced that the U.S. FDA has granted Fast Track Designation to AP-SA02, the company’s intravenously administered Staphylococcus aureus multi-phage product candidate, f...
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 ...